Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 5/20 | 0.63 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.63 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.63 |
| ▸ | ALDH1A1 | P00352 | 8/20 | 0.44 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.42 |
| ▸ | CD44 | P16070 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 3/20 | 0.41 |
| ▸ | POLB | P06746 | 2/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | APAF1 | O14727 | 1/20 | 0.41 |
| ▸ | THRB | P10828 | 1/20 | 0.41 |
| ▸ | NR4A1 | P22736 | 1/20 | 0.41 |
| ▸ | RECQL | P46063 | 1/20 | 0.41 |
| ▸ | BLM | P54132 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | PTPN11 | Q06124 | 1/20 | 0.41 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.41 |
| ▸ | UHRF1 | Q96T88 | 1/20 | 0.39 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Benzene SCHEMBL27906205 | 0.95 | CYP3A4 (0.57) | TSHRCYP3A4MAPK1ALDH1A1TDP1 | |
| SCHEMBL3439643 | 0.88 | CYP3A4 (0.63) | TSHRCYP3A4MAPK1ALDH1A1TDP1 | |
| SCHEMBL8121628 | 0.88 | CYP3A4 (0.55) | TSHRCYP3A4MAPK1ALDH1A1TDP1 | |
| SCHEMBL2321600 | 0.86 | CYP3A4 (0.52) | TSHRCYP3A4MAPK1ALDH1A1TDP1 | |
| SCHEMBL9068413 | 0.86 | CYP3A4 (0.46) | TSHRCYP3A4MAPK1ALDH1A1TDP1 | |
| SCHEMBL10620546 | 0.83 | CYP3A4 (0.43) | TSHRCYP3A4MAPK1ALDH1A1TDP1 | |
| SCHEMBL272760 | 0.82 | CYP3A4 (0.63) | TSHRCYP3A4MAPK1ALDH1A1TDP1 | |
| SCHEMBL15515282 | 0.79 | CYP3A4 (0.46) | TSHRCYP3A4MAPK1ALDH1A1TDP1 | |
| SCHEMBL5238545 | 0.79 | CD44 (0.65) | TSHRCYP3A4MAPK1ALDH1A1TDP1 | |
| SCHEMBL832549 | 0.79 | KDM1A (0.41) | TSHRCYP3A4MAPK1ALDH1A1TDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 65 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260008777-A1 | INHIBITORS OF PROTEIN TYROSINE PHOSPHATASE, COMPOSITIONS, AND METHODS OF USE | BRISTOL-MYERS SQUIBB COMPANY (US) | 2026-01-08 | — | — | US | disclosed |
| US-11856955-B2 | Binary compositions as disruptors of Orco-mediated odorant sensing | VANDERBILT UNIVERSITY (US) | 2024-01-02 | — | — | US | disclosed |
| US-11856955-B2 | Binary compositions as disruptors of Orco-mediated odorant sensing | VANDERBILT UNIVERSITY (US) | 2024-01-02 | — | — | US | disclosed |
| CN-111683955-B | Compound and organic light-emitting element comprising same | 株式会社LG化学 | 2023-12-08 | — | — | CN | disclosed |
| WO-2022242521-A1 | CONDENSED AZACYCLIC COMPOUND, USE THEREOF, AND ORGANIC ELECTROLUMINESCENT DEVICE COMPRISING CONDENSED AZACYCLIC COMPOUND | 浙江虹舞科技有限公司 | 2022-11-24 | — | — | WO | disclosed |
| CN-115368370-A | Condensed nitrogen heterocyclic compound, application thereof and organic electroluminescent device containing compound | 浙江虹舞科技有限公司 | 2022-11-22 | — | — | CN | disclosed |
| US-10898516-B2 | Compositions and methods of treating diabetic retinopathy | CASE WESTERN UNIVERSITY (US) | 2021-01-26 | — | — | US | disclosed |
| CN-111683955-A | Compound and organic light-emitting element comprising same | 株式会社LG化学 | 2020-09-18 | — | — | CN | disclosed |
| US-10568851-B2 | Compounds and methods of treating ocular disorders | CASE WESTERN RESERVE UNIVERSITY (US) | 2020-02-25 | — | — | US | disclosed |
| US-10426773-B2 | Systems pharmacology for treating ocular disorders | CASE WESTERN UNIVERSITY (US) | 2019-10-01 | — | — | US | disclosed |
| WO-2007047496-A2 | ACYLATED SPIROPIPERIDINE DERIVATIVES AS MELANOCORTIN-4 RECEPTOR MODULATORS | MERCK & CO., INC. (US) | 2007-04-26 | — | — | WO | disclosed |
| US-20070037851-A1 | Inhibits binding of CCR3 ligands such as eotaxins to their target cells; inhibits physiological effects of binding; therapeutic and prophylactic agents for asthma, rhinitis, dermatitis, urticaria, conjunctivitis, inflammatory bowel; tissue infiltration of eosinophils, basophils, activated T cells | TEIJIN LIMITED, A JAPANESE BODY CORPORATE (JP) | 2007-02-15 | — | — | US | disclosed |
| US-20070032525-A1 | Piperidine derivatives having ccr3 antagonism | TEIJIN LIMITED, A JAPANESE BODY CORPORATE (JP) | 2007-02-08 | — | — | US | disclosed |
| US-20060183904-A1 | Acylated spiropiperidine derivatives as melanocortin-4 receptor agonists | MERCK SHARP & DOHME CORP. | 2006-08-17 | — | — | US | disclosed |
| EP-1613601-A2 | ACYLATED SPIROPIPERIDINE DERIVATIVES AS MELANOCORTIN-4 RECEPTOR AGONISTS | Merck & Co. Inc. (US) | 2006-01-11 | — | — | EP | disclosed |
| CN-1665804-A | 4, 4-disubstituted piperidine derivatives having CCR3 antagonism | TEIJIN LTD (JP) | 2005-09-07 | — | — | CN | disclosed |
| CN-1659161-A | Piperidine derivatives having CCR3 antagonism | TEIJIN LTD (JP) | 2005-08-24 | — | — | CN | disclosed |
| EP-1505067-A1 | 4,4-DISUBSTITUTED PIPERIDINE DERIVATIVES HAVING CCR3 ANTAGONISM | TEIJIN LIMITED (JP) | 2005-02-09 | — | — | EP | disclosed |
| EP-1502916-A1 | PIPERIDINE DERIVATIVES HAVING CCR3 ANTAGONISM | TEIJIN LIMITED (JP) | 2005-02-02 | — | — | EP | disclosed |
| WO-2004089307-A2 | ACYLATED SPIROPIPERIDINE DERIVATIVES AS MELANOCORTIN-4 RECEPTOR AGONISTS | MERCK & CO. INC. (US) | 2004-10-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11856955-B2 | Binary compositions as disruptors of Orco-mediated odorant sensing | OR51E2, OR10J3, ORC3 | TSHR 1036/4885CYP3A4 2641/4885MAPK1 2109/4885 |
| US-10426773-B2 | Systems pharmacology for treating ocular disorders | GRK1, MTNR1A, MTNR1B | TSHR 96/4885CYP3A4 1389/4885MAPK1 1728/4885 |
| US-20060183904-A1 | Acylated spiropiperidine derivatives as melanocortin-4 receptor agonists | MC4R, MC5R, MC3R | TSHR 436/4885CYP3A4 735/4885MAPK1 2952/4885 |
| US-20070032525-A1 | Piperidine derivatives having ccr3 antagonism | CCR3, CCR1, CCR4 | TSHR 3393/4885CYP3A4 1305/4885MAPK1 1077/4885 |
| US-20260008777-A1 | INHIBITORS OF PROTEIN TYROSINE PHOSPHATASE, COMPOSITIONS, AND METHODS OF USE | PTPRO, PTPRC, PTPRR | TSHR 248/4885CYP3A4 1270/4885MAPK1 667/4885 |
| US-20070037851-A1 | Inhibits binding of CCR3 ligands such as eotaxins to their target cells; inhibits physiological effects of binding; therapeutic and prophylactic agents for asthma, rhinitis, dermatitis, urticaria, conjunctivitis, inflammatory bowel; tissue infiltration of eosinophils, basophils, activated T cells | CCR3, CCR1, CCR4 | TSHR 2336/4885CYP3A4 1224/4885MAPK1 591/4885 |
| US-10568851-B2 | Compounds and methods of treating ocular disorders | ALDH1A2, TXNRD2, TXNRD1 | TSHR 1003/4885CYP3A4 4631/4885MAPK1 1754/4885 |
| US-10898516-B2 | Compositions and methods of treating diabetic retinopathy | GPR119, ARRB1, GRK1 | TSHR 911/4885CYP3A4 4809/4885MAPK1 861/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.